McKesson

McKesson Corporation distributes roughly one-third of pharmaceuticals in North America, connecting manufacturers with pharmacies, hospitals, and clinics through high-volume logistics and cold-chain infrastructure.

The company also operates oncology and specialty provider networks, health IT through former RelayHealth and other assets, and international distribution joint ventures. Vertical touches span from factory gate to pharmacy shelf without owning retail pharmacies at national scale like CVS.

Distributor economics rely on manufacturer chargebacks, generic sourcing programs, and service fees rather than transparent markups on branded drugs. That opacity complicates antitrust analysis when independent pharmacies allege discriminatory generic pricing tiers.

McKesson participated in opioid settlement frameworks addressing distribution monitoring failures—a distinct legal track from competition law but shaping public scrutiny of distributor concentration.

Proposed retail pharmacy mergers indirectly reshape distributor bargaining dynamics: larger retail buyers extract better terms, squeezing independents who lack consolidated purchase volume.

Three-firm wholesale concentration prompts periodic congressional hearings on drug pricing, with theories that parallel fee structures and shared customers enable coordinated margin management even absent explicit collusion.

Vertical foreclosure arises when distributor-owned specialty practices prefer in-network dispensing or data tools that steer physician prescribing toward affiliated pharmacies.

FTC pharmacy chain merger reviews examine whether combined retail–PBM entities leverage distributor rebates; McKesson's neutral-wholesaler role is still implicated when exclusivity on generic compliance programs binds small pharmacies.

Group purchasing and RFQ processes for hospital systems can embed minimum volume commitments across the Big Three, limiting entrant regional distributors' ability to win IDN contracts.

Patients rarely interact with McKesson directly, yet distributor generic pricing tiers influence whether neighborhood pharmacies can afford to fill low-margin scripts.

Independent pharmacists report administrative fees and inventory minimums that mirror complaints in grocery slotting—barriers justified as supply-chain efficiency or criticized as exclusionary.

Hospital buyers negotiating oncology bundles may face incentives to use McKesson-affiliated infusion networks for rebate capture, affecting patient site-of-care options.